ArticlePakistan journal of medical sciences2026
Impact of Low Dose Prophylaxis (LDP) on spontaneous bleeds in Hemophilia-A: A Bicentre study from Pakistan.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Objectives: Hemophilia-A is a bleeding disorder characterized by musculoskeletal bleeding. Standard dose factor replacement (SDP) is the mainstay of treatment for severe or moderately severe HA patients however it is fraught with increased cost and burden on health care system. Low dose prophylaxis (LDP) has gained popularity in low- and middle-income settings (LMIC) as being more feasible and cost effective. The aim of this study was to establish efficacy of low dose prophylaxis of clotting factor concentrates (CFCs) as primary or secondary prophylaxis strategy on the bleeding outcomes of pediatric severe HA patients. Methodology: This bicentre prospective collaborative study from the Hemophilia Patient Welfare Society (HPWS) and the World Federation of Hemophilia (WFH) commenced at Rawalpindi & Lahore Hemophilia Treatment Centers (HTCs) in Pakistan from January 2017 to January 2023.This study assessed the annualized bleeding rates (ABR) before and after LDP in pediatric HA patients as primary or secondary prophylaxis. Results: This bicenter study from Lahore and Rawalpindi reports statistically significant reduction in ABR after LDP (p=<0.0001) in 46 pediatric male patients. The study reports good compliance, reduced ABR and no development of new inhibitors in these patients all followed for one year post LDP start. Conclusion: This study shows the efficacy of LDP in pediatric HA patients in reducing ABR. This also gives a safety signal in terms of no major breakthrough bleeds and no new inhibitor formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.